studies indicate that transfer of a single member of the Pgp genes is sufficient to mediate multidrug resistance. Analysis of Pgp cDNAs revealed that Pgp has remarkable structural homology to a number of bacterial transport proteins, and that it has features (ATP-binding and pore-forming domains) of a membrane pump protein. Thus it is envisioned that a variety of compounds (including many anticancer drugs) are exported from mammalian cells via this molecular pump mechanism.
Despite this understanding of Pgp function, many basic questions remain unanswered. These include: (1) In order to understand the way in which antibodies recognise and bind to antigenic surfaces, detailed information about the interactions between antibody and its epitope must be defined. It is now possible to explore the molecular basis of antibody affinity and specificity by combining the techniques of molecular modelling using computer graphics, energy calculations and protein engineering using site directed mutagenesis.
A panel of five monoclonal antibodies (mAb) (gloops 1-5) are used in our laboratory to study antibody:protein antigen interactions. These antibodies were raised against the isolated 'loop' peptide, residues 57-83 of hen egg-white lysozymes (HEWL) and selected by cross-reactivity with native lysozyme. The antibodies are classified into three groups which recognise dissimilar but overlapping epitopes. In addition we are examining antibody: DNA/RNA antigen interactions with mAbs derived from systemic lupus erythematosus prone mice.
Our studies have shown that we are able to specifically engineer antibodies with altered affinities from the native protein. The topographical surface of the anti-lysozyme antibodies can be altered by a small number of changes, resulting in effects on antibody binding, ranging from complete abolition through to increased affinity for antigen. From these studies we hope to establish the rules governing antibody:antigen interactions and that an understanding of such interactions will enable us to design antibodies of clinical and industrial importance. The primary immune response of C57B1/6 mice to the hapten NP (4-hydroxy-3-nitrophenylacetyl) is characterised by light chain-bearing antibodies of germline Vh gene sequence. Upon secondary challenge with the hapten, antibodies of increased affinity are observed which are extensively mutated throughout their V regions. Amongst the mutations observed, a tryptophan to leucine exchange (TCG-TTG) at position 33 of the heavy chain is repeatedly observed in independently isolated hybridomas. We have used site-specific mutagenesis to introduce this single exchange into a primary response antibody and show that the hapten-binding affinity is increased by up to 10-fold. We have also shown that restoring a tryptophan residue at position 33 of a secondary response antibody (3B44) causes a 10-fold decrease in affinity, implying that all other somatic mutations in 3B44 were irrelevant to a selection of improved hapten binding in vivo. However, in rare cases where the trpleu exchange is not observed in the secondary response, we have shown, by recombinant antibody construction, that structures in the third complementary-determining region may influence selection of other mutations in the VH region which lead to increased affinity. The cell fusion of two Ig producing cell lines results in the codominant expression of all of the parental cell derived Ig chains. For a cell making two Ig heavy chains and two Ig light chains a random association of all chains results in ten possible configurations of secreted antibody species. The interest in these antibodies for therapy stems from the biological properties of different species within the complex mixture. In addition to the properties which depend upon the interaction of different Ig isotypes with human effector mechanisms there are unique properties which result from the different binding specificities for antigen. For example, certain species of antibody are monovalent for binding to a given antigen. Such monovalent antibodies with specificities for modulating cell surface antigens seem to be more efficient than the equivalent bivalent antibodies at lysing target cells with complement. Monovalent CD3 antibody is currently being used therapeutically. Another of the components of the mixture has dual specificity for the two different antigens recognised by the parental antibody types. These bispecific antibodies are capable of targeting drugs or toxins to cells expressing appropriate cell surface antigens. Also of interest is the ability of these bi-specific antibodies to induce very potent tumour cell killing by activated T-cell blasts when the bi-specific antibody is used to cross-link a component of the T-cell receptor complex and a suitable cell surface antigen on the target cell. Calculations based upon cell and antigen densities and scintillation camera sensitivities suggest that radioimmunoimaging (RII) has the potential in theory to detect cancers smaller than currently possible by existing imaging techniques and prior to likelihood of metastasis. While clinical trials of RII have not been extensive thus far, they have provided results far short of that theoretically possible. Detection of 60-90% of lesions and lesions not detectable by other methods has been reported for several different antibody-radionuclide systems, but lesions with diameters less than 1-2 cm have often been missed. Many factors degrade the imaging potential of RII. Some of these are amenable to solution through improved radionuclides, radiochemistry, antibodies and so forth. More challenging obstacles relate to delivery of the radionuclide to the tumour. Creativity has already led to several proposals for enhanced delivery. These include the use of radiation, biological response modifiers, antibody fragments and hybrid antibodies. It seems wiser at this stage of development to ask the right questions rather than make predictions for the future. The The techniques of molecular biology and modern immunology give us many molecules which have potential for targeting to cancer. Only quantitative clinical study can identify those which will be of value to patients. Methods for quantitative clinical testing are now being developed with radiolabelled antibodies. Three-dimensional (SPET) gammacamera imaging is necessary for accurate radiation dose measurements and these must be done from the day of administration for 2-3 weeks. Means of avoiding the inaccuracies inherent in the method have been developed. With this system great variation in the efficiency in antibody localisation has been shown and some prediction of response is possible in patients with colorectal cancer treated with iodine13 3-labelled antibody to CEA. It is also evident that the best therapeutic ratio (11:1) occurs after the first two days, especially if second antibody is given. This favours the use of dual phase system for targeted therapy. Even so it is likely that multiple dose therapy will be needed and prevention of the human antimouse response will be necessary. We have shown that cyclosporin A can delay and reduce the intensity of human antimouse antibody production so that up to four times as many doses of antibody therapy can be given in man. This ability to give repeated therapy and to measure the efficiency of targeting provides the means to select patients for effective anti-tumour therapy. One of the features that distinguishes tumour cells from normal cells is the ability of the former to grow rapidly in low concentrations of serum. Investigations of this observation at the molecular level have revealed that molecules normally involved in growth control are frequently aberrantly expressed by tumour cells. Many of the genes encoding such molecules can be activated by mutation to forms capable of transforming cells. These genes, termed oncogenes, encode growth factors, growth factor receptors and molecules in the cytoplasm and cell nucleus involved in transduction of growth regulatory signals.
We have investigated the production of growth factors and their receptors in a variety of primary human tumour biopsies. The epidermal growth factor receptors and the structurally related c-erbB-2 protein have been found to be frequently over-expressed in a variety of human carcinomas as assessed by immunohistological staining and Western blotting. The number of gene copies of both these molecules are also often increased in tumours.
We have examined the role of these changes in the instigation and maintenance of the transformed phenotype as well as their value in prediction of tumour behaviour. We have previously reported that in rats injected with intact murine anti-human tumour antibody, B72.3, labelled with either 12 I(I) or I 1ln(In), the liver uptake of radiolabel is predominantly due to accumulation by the liver parenchymal cells. To determine the effect of removal of the Fc portion on liver cell uptake we have measured the uptake of radiolabel by rat liver cells of animals injected i.v. with either intact B72.3 and its F(ab')2 labelled with either I or In. One hour after administration, liver cells, obtained by collagenase perfusion, were separated into parenchymal (PC) and nonparenchymal (NPC) fractions using Percoll gradients. 77.9% and 80.8% of the label recovered was PC-associated when Ior In-labelled B72.3 was administered, while after I-and In-F(ab'2) administration, 96% and 94.6% of the label was recovered in the PC fractions. The absolute uptake of In-F(ab')2 was similar to that of I-F(ab')2 but was 54% of that seen with the IgG. To determine whether the lower absolute liver uptake of F(ab')2 was due to the absence of Fc binding or was a result of more rapid blood clearance, the uptake of B72.3 and its F(ab')2 labelled with I or In was measured in the perfused rat liver. When compared with data obtained from livers of rats injected with labelled antibodies, the uptake of I-and In-B72.3 in the perfused liver was reduced by 57.2% and 92.3%, respectively, by removal of Fc. Thus Fc binding is a major component contributing to liver uptake of IgG. When the liver uptake of B72.3 and its F(ab')2 labelled with 99Tcm using rabbit metallothionein as the radionuclide chelator was studied, >84% of recovered 99Tcm was in the PC fraction. In summary, PC are the major liver cell of radionuclide accretion regardless of either the specific radionuclide or whether the label is attached to IgG or F(ab')2. The use of colloidal gold and colloidal gold followed by silver enhancement are two highly sensitive and accurate techniques for the visualisation of target molecules identified by monoclonal antibodies (MAbs). Gold probes were particularly useful when used at two different particle sizes (5 and 20nm in diameter) in a double labelling method for the identification of two antigens on the same grid. We have also combined gold and gold/silver staining in a double staining technique for the simultaneous localization of breast cancer-associated antigens using BCD-E8 and BCD-F9 Mabs. These techniques have also been used to demonstrate the internalisation of the gold-labelled BCD-F9 MAb in MCF-7 cells by warming for 30min at 37°C. We conclude that colloidal gold and gold/silver markers constitute valuable and versatile tools for the ultrastructural localisation and quantitation of target molecules identified by MAbs and that further development of these techniques may have an important impact on the development and use of MAbs in oncology. We report that complexes of the above named radionuclides with DOTA have been synthesised and their kinetics of isotope exchange and dissociated in aqueous media examined. All complexes are kinetically inert from pH 3 to 9.
In view of the likely importance of 212Pb as a carrier of alpha emitter 212Bi for radioimmunotherapy, we have carefully examined the retention of the 212Bi in DOTA when produced by radiodecay of the parent 212Pb and are able to report substantial retention of the daughter radionuclide. Recent developments in the differential diagnosis of the small cell cancers of childhood have centered on the use of monoclonal antibodies to identify cell-type specific antigens in specific types of neoplasm. In addition, radiolabelled monoclonal antibodies have proven useful in tumour imaging and in the treatment of diffuse neoplastic meningitis.
In an attempt to extend the use of monoclonal antibodies into differential glioma diagnosis, antibodies were raised against three malignant gliomas, using standard techniques. A total of 281 hybridoma clones were raised and tested for reactivity against the glioma used for the initial immunisation. Six antibodies were selected for further study on the basis of their strong anti-glioma reactivity with nonneoplastic brain tissue.
These antibodies were tested against a large panel of glial and non-glial brain tumours, and each showed a highly characteristic staining pattern. Th]ie patterns of reactivity seen in sections stained with these antibodies suggest that each antibody stains specific groups of cells within glial tumours. The specificity shown by these antibodies for glioma tissue as opposed to normal brain, and their apparent specificity for particular sub-sets of glioma cells suggest that these antibodies may prove useful in the diagnosis, imaging and therapy of malignant gliomas. Ten patients with relapsed gliomas grade III, IV and a patient with astrocytoma grade I were studied with 1311_ H17E2. Additionally, two patients with glioma III, IV were studied with a non-specific anti-idiotype 2118 MCA. 1.5-2.0mCi (55-74MBq) were administered intracarotically (i.c.) or intravenously (i.v.). Immunoscans were taken at 0, 2, 24, 48 and 72 h and kinetics of the MCAs were studied. See We used nude rats bearing cytokeratin-positive solid HeLa cell carcinomas on their hind leg. The binding of monoclonal anti-cytokeratin antibodies to the tumour was demonstrated in vitro by immunohistochemical staining and in vivo by means of radioimmunodetection with 125I-labelled antibodies. The animals were preinjected i.v. with 'cold' biotinconjugated anti-cytokeratin antibodies. At a later time 1251_ labelled streptavidin was administered i.v. In another approach the animals received an additional injection with a specific anti-antibody to the previously administered anticytokeratin antibody in order to reduce free antibodies in the circulation. In the streptavidin-biotin system the tumour could be localised within 60min, whereas it took at least three days with the directly labelled antibody. Using the anti-antibody the tumour could be seen 15min after injection. A limitation of the system was some antibodyindependent binding of streptavidin to the tumour as well as to other organs, especially kidney and liver. The presence of tumour involved nodes in patients with breast cancer can at present only be demonstrated following surgical resection. We have assessed the uptake of two 1231-labelled MoAbs, HMFG1 and SM3 in patients undergoing mastectomy with axillary clearance. Fourteen patients have been studied, 4 with HMFG1 injected subcutaneously (s.c.) into the finger webs of both hands, 4 with SM3 injected s.c., and 6 with SM3 injected intravenously (i.v.).
Patients were imaged at 1, 4 and 20h after injection and blood and urine samples were collected. The resected specimen was imaged, the nodes and tumour then dissected, counted individually and examined histologically.
Imaging showed symmetrical uptake in both axillae following subcutaneous injection, and no tumour uptake was observed after IV injection of SM3. In an attempt preoperatively to detect clinical and subclinical axillary lymph node metastases in breast cancer, we used 131I-labelled MoAb HMFG2 and HMFG1 F(ab')2. We studied 10 patients with clinically obvious axillary lymph node disease (group A), 10 patients with clinically negative axilla (group B), using MoAb HMFG2, 5 patients with clinically negative axilla (group C), using MoAb HMFG1 F(ab')2 and 6 patients with clinically positive axillae (group D) using non-specific MoAb 11.4.1 and 4C4. All patients had clinical diagnosis of breast cancer. Each patient received 1-1.5mCi as a subcutaneous injection into the webs between the 2nd and 3rd fingers of both hands. The patients were scanned at 24-96 h post-injection. In group A, 7 patients had positive scans and 3 negative. The histology and immunoperoxidase staining confirmed the presence of tumour in the lymph nodes in all patients. In group B there were 4 true positive scans, 4 true negative, 1 false positive and 1 false negative. Lymph node involvement was histologically confirmed in 5 patients. In group C there were 4 true negative scans. In 1 patient the MoAb stopped in the middle of the right arm, due to lymphatic obstruction. The histology confirmed the absence of tumour in the lymph nodes. In group D, there were 3 true negative scans with MoAb 11.4.1 and 3 true negative scans with MoAb 4C4. The presence of tumour was histologically confirmed in all patients.
This preliminary study suggests that this approach can preoperatively detect metastatic tumour in axillary lymph nodes and be of value in the diagnosis and staging of breast cancer.
A Japanese phase II study of immunoscintigraphy with 131I anti CEA and anti CA19-9 monoclonal antibodies
Gunma University and five other Institutes, Japan.
The purpose of this study was to evaluate the safety and clinical usefulness of immunoscintigraphy with 1311 anti CEA and 1311 anti CA 19-9 monoclonal antibody cocktail (IMACIS 1) which was provided by International CIS (France). Thirty-six patients with proven cancer in six hospitals were entered in the phase II study. Images were taken with a gamma camera after injection of IMACIS 1 collecting 300k counts for each view.
Changes of the heart rates, temperature, blood pressure, respiratory rates and other parameters were obtained. Blood clearance, urinary excretion and HAMA response were also investigated.
Positive scintigrams were obtained in 30/36 (83%) patients and in 39/52 (75%) cancer sites. Blood clearance curves constituted of two exponential components with mean T1/2 of 7.5 h and 35.4 h. Fifty per cent of the injected dose was excreted in the urine by the 5th day after injection. No significant changes of the heart rates, temperature, blood pressure, respiratory rates and clinical laboratory data were observed. Significant elevation of HAMA titre was not shown. No adverse reactions were observed in any of the patients.
On the basis of these results, we plan to commence phase III clinical trials in Japan. Radiation dosimetry is important both for treatment planning and for evaluating the success of radiation therapy. Biological response to alpha radiation may be highly variable at a given absorbed dose, depending on the local distribution of alpha-particle energy. Predicting the effectiveness of alpha-particle radiation in radioimmunotherapy depends on adequately characterising the distribution of energy at the cellular level. Four factors characterise the microdosimetry of alpha-particle interactions with living matter: (1) the average (absorbed) dose; (2) the probability density in specific energy (or distribution of doses to small targets); (3) the delta function (or fraction of targets completely missed); and (4) the mean number of hits per target. Determination of these elements requires careful consideration of the spatial distribution of alpha-emitting sources with respect to targets, the initial alpha-particle energy, the number of emissions per source, the relative specific ionisation as a function of track length and the size of the target (such as the diameter of the cell nucleus). Although precise correlations have not yet been developed between probability density in specific energy and the tumour-eradication effectiveness of alpha-emitting radioimmunoconjugates, such relationships will become apparent with further experimentation and the careful application of microdosimetric principles. Immunotoxins were synthesised by attaching ricin A-chain, abrin A-chain, and two ribosome-inactivating proteins (RIPs), gelonin and momordin, to a single monoclonal antibody LICR-LOND-Fib 75. All four immunotoxins were powerfully and specifically cytotoxic to the human EJ bladder carcinoma cell line: protein synthesis by EJ cells growing in tissue culture was inhibited by 50% at immunotoxin concentrations ranging between 7 x 1011M and 5 x10-10 M.
The blood clearance of immunotoxins after intravenous administration to normal rats was measured in the serum using a solid-phase ELISA specific for each type of toxin Achain or RIP. A substantial proportion of Fib 75-ricin A was lost from the circulation within 2 min of injection consistent with hepatic recognition of oligosaccharide chains present on ricin A-chain. In contrast, the immunotoxin containing abrin A-chain, which is not glycosylated, was cleared much less rapidly so that the serum concentration of Fib 75-abrin A The distribution kinetics of antibodies and antibody-toxin conjugates result in 'areas under the curve' which are less favourable for the delivery of toxic substances to tumours than is required for major therapeutic advance. The specificity of antibodies can be used more effectively by delaying the delivery of a toxin to a time when the tumour/nontumour concentration ratios are most favourable and this requires 'capture' of the toxin or 'activation' of the toxin at the tumour site. It would also be advantageous if some form of amplification could be achieved at tumour sites.
These considerations have led to a two-phase approach. In the first phase a conjugate comprising an antibody fragment coupled to a non-mammalian enzyme is injected and allowed to localise at tumour sites. This is followed after an appropriate interval by a prodrug characterised by being readily diffusible at least through extracellular fluids and by being relatively stable by virtue of a protective group which acts as substrate for the targeted enzyme. Enzymatic action converts the product into a highly toxic agent which can diffuse readily through tumour extracellular fluids and enter cells but which ideally has a short half-life so that it reaches normal renewal tissues only in limited amounts.
Experimental data confirm the feasibility of this approach. The use of monoclonal antibodies for diagnostic and therapeutic purposes depends on the uptake and retention of the antibodies in the target neoplastic tissues. The purpose of the study was to examine the biodistribution of specific and nonspecific antibodies in resected human colon tumours.
After resection of the colon tumour, the supplying artery was canulated and perfused with fresh frozen plasma and Heparin. Continuous control of pressure, flow, temperature, pH and various metabolic parameters were performed after administration of 131I-labelled anti-CEA antibody. Highly differentiated adenocarcinomas of the colon showed a much higher antibody uptake, than undifferentiated tumours. Between 3 and 7% of the injected antibody was found in the tumour tissue. Autoradiography showed inhomogeneous binding in the tumour tissue. The non-specific antibodyperfusion showed no tumour binding.
We conclude that the ex vivo perfusion of resected colon carcinomas can be used to measure the kinetics of binding and clearance of monoclonal antibodies in tumour tissue by direct scintigraphy. The cellular biodistribution of the antibody can be documented through autoradiography. An anti-CEA antibody A5B7 has been conjugated with DTPA (using N-hydroxysuccinamide) and DHDE (N,N' -di(hydroxycarbonylmethyl) -N,N'((2-hydroxy)hydroxycarbonylbenzyl)diaminoethane) (using a water soluble carbodiimide).
Radioimmunoassay and FPLC studies showed that the conjugation procedure has not impaired the CEA binding ability of the antibody or induced aggregate formation.
Biodistribution and imaging studies of indium-11 labelled conjugates have been carried out in nude mice bearing the human colon carcinoma xenograft LS-174T.
Results showed favourable tumour to tissue ratios for the DTPA conjugate, enabling tumours to be visualised by gamma-camera imaging. Tumour to tissue ratios for the DHDE conjugate were less favourable. Mouse IgGi monoclonal antibodies (MAbs) directed against human prostatic acid phosphatase were used for radioimaging of prostatic cancer metastases in our laboratory. We have developed two different two-step methods to purify these MAbs from cell culture media containing 1-5% fetal calf serum. Methods are based on ion exchange and hydrophobic interaction chromatographies. The main contaminants, bovine albumin and transferrin are effectively removed by these methods. Purity analyses made by SDS-PAGE and sterility and pyrogen tests show that these MAb meet the requirements given by FDA for MAbs used for in vivo purposes.
We have also digested IgGI to F(ab')2-fragments using pepsin and papain digestions. Papain digestion was shown to be more efficient in F(ab)2-fragmentation for radioimaging purposes. The yield of F(ab')2-fragments from papain digestion was 50+5% of the theoretical maximum. Both pepsin and papain digestions gave F(ab')2-fragments with immunoreactivity and affinity identical to those of the original IgGI. t1tAg by virtue of its 7.45 days T1/2 and beta emission appeared to be a candidate radionuclide for radioimmunotherapy. We describe the preparation of radio silver from 110Pd and the separation of 111Ag from 11 Pd by anion exchange chromatography.
I°IPd was irradiated for 24 h in a neutron flux of Ix 102ncm-2s-I at the APSARA reactor BARC, Bombay. Six hours after irradiation the sample was dissolved in 10ml 10M HCI and applied to a Dowex-I column (8% cross-linked 100-200 dry mesh, Sigma). The silver is eluted from this column using 1OM HCI and Pd is retained in the column. The product is over 99.5% pure and appears suitable for further processing for radiolabelling. The technique was earlier standardised using inactive Pd and Ag. A monoclonal antibody, anti-HeLa, was developed against HeLa cell line (Human Ca Cervix line). The specific reactivity of the MoAb with epitope on the surface of the HeLa cells was confirmed both by ELISA as well as by indirect immunoperoxidase staining. Further quantitative reactivity with HeLa cells was confirmed by RIA. The reactivity of the anti-HeLa was tested against a panel of malignant tissues by indirect immunoperoxidase method. Anti-HeLa antibody showed very strong positivity with squamous cell carcinoma of cervix but showed only mild positive reaction with squamous cell carcinoma of buccal mucosa and oesophagus. Anti-HeLa antibody showed mild reactivity with nonmalignant cervix. Anti-HeLa monoclonal showed reaction similar to that of anti-keratin antibodies reported by Debus (1982 Debus ( , 1984 and Ramackers (1983) . The aim of this pilot study was to examine the feasibility of using the SDE technique to ethance the information gathered from radioimmunoscintigraphic examination of patients with colorectal cancer. It was also hoped that the technique would lead to the detection of small tumour masses due to the increased sensitivity of the Tc-labelled nanocolloid. SDE planar and single photon emission computed tomographic (SPECT) images were obtained 4-6 days post infusion with Imacis-l (131I-labelled murine anti-CEA, anti-CA-19.9). The SDE method requires that an injection of 99Tcm-nanocolloid is given 24 h prior to final imaging.
One patient had a negative scan and was clinically asymptomatic despite a rising serum CA-19.9 (125Uml-1). Three patients with rising levels of CEA and CA-19.9 had positive SDE scans. Malignancy was confirmed visually (endoscopy) and histologically. Two patients had primary tumours confirmed at operation. The third case was of particular interest in that Imacis-1 and nonocolloid accumulations were found at colonoscopy to correspond to polyps (3-5 mm). On external counting the iodine label was present in one metaplastic and one dysplastic polyp whilst the 99Tcm-nanocolloid was present in all three polyps. These initial results are encouraging.
Pre-targeted immunoscintigraphy in patients with non-small cell lung cancer (NSCC) using streptavidin conjugated HMFG1 and indium-11-labelled biotin We describe a new method for in vivo labelling monoclonal antibodies using streptavidin conjugated monoclonal antibody given first (pre-targeted), followed by indium-111-labelled biotin. We studied four patients with lung cancer (NSCC) to identify toxicity, localising efficiency, biodistribution and pharmacokinetics. We administered i.v. unlabelled HMFG1 antibody conjugated with streptavidin followed 3 days later by indium-111-labelled biotin. Twenty-four hours after 1111n-biotin administration the uptake by each kidney was 5.0% and by liver 2.0% of the injected dose. Maximum tumour concentrations were achieved in 2h but the optimal time for imaging was at 24h with higher tumour to normal lung ratios. Radioactivity in the serum had a T =/2a 2min and T,/2b= 4h. The cumulative urinary excretion of radioactivity over 24h was 78% of the injected dose, of which 70% was excreted in the first 6h. No toxicity was observed. These preliminary results indicate an improvement in tumour to normal tissue ratios, with the exception of kidneys.
Kinetics, quantitative analysis and immunolocalisation using radiolabelled HMFG1-monoclonal antibody in patients with HMFG1, IgG and F(ab')2 fragments, radiolabelled with indium-111, were used to study patients with breast cancer. Twenty-four patients with primary breast cancer underwent tumour resection and quantitation of the radioactivity in tumour versus normal tissue following administration of specific and non-specific antibodies. The mean tumour uptake of HMFGI-F(ab)2 fragments at 24 h was 5.8 x 10-3% of injected dose per gram of tissue (% ID g'-).
This was higher than the intact antibody 2.6 x 10-3 % ID g-1 (P <0.05), but at 48 h there was no significant difference, 5.7 x 10-3 and 7.4 x 10-3% ID g-respectively. The mean tumour uptake with the specific antibody was higher than the non-specific antibody of the same subclass, 2.3 x 10-5% ID g-1 (P<0.05). Lymph node metastases, interestingly, showed higher antibody uptake than the corresponding primary tumours 8.0 x 10-3% ID g -I (P < 0.05). Fifteen patients, were imaged using I11n-F(ab')2 HMFGI-F(ab')2 fragments. We observed positive localisation in 3 out of 7 with primary lesions, in 4 out of 6 with bone metastases, in 2 out of 4 with skin infiltration, in 1 out of 2 with lymph node and in 1 out of 2 with liver metastases. The optimal time for imaging was 48 h. All patients had significant concentration of "1'In in the liver.
We conclude that HMFGI-F(ab')2 fragments can localise specifically and faster than the intact IgG in breast cancer. However, this method needs further improvement prior to becoming a clinically useful method for staging breast Immunoscintigraphy was performed in 21 patients using iodine-123-labelled monoclonal antibodies against epidermal growth factor receptor (EGFRI) and placental alkaline phosphatase (Hl7E2). Ten patients were also imaged using a non-specific antibody (11.4.1) of the same immunoglobulin subclass. The specificity of targeting was confirmed by comparing imaging obtained by specific and non-specific antibodies. In addition, quantitative evaluation of the antibody uptake in tumour versus normal tissue was performed in 7 patients using the paired antibody technique, following tumour resection.
Seven patients with recurrent brain glioma (grade III or IV) who previously showed good localisation of radiolabelled antibody were treated with 40-140mCi of iodine-131-labelled antibody delivered to the tumour area intravenously or by infusion into the internal carotid artery. Four patients showed clinical improvement lasting from 6 months to 2 years. One patient continues in remission 2 years after therapy but the other 3 who responded initially, relapsed 6-12 months after therapy and died.
No major toxicity was attributable to antibody guided irradiation. The patient who received 140mCi developed a moderate but reversible thrombocytopenia and neutropenia. These promising but preliminary results should be explored further in randomised trials. Nude mice bearing subcutaneous human colorectal carcinoma (LoVo), were exposed to single doses of external irradiation of 40 to 160Gy, followed 24h later by 1111n-labelled monoclonal antibody. Two antibodies were selected, AUA1 as specific and HMFG1 as non-specific. Animals were sacrificed 3 days after antibody administration and binding of monoclonal antibodies to tumour and normal tissues was measured. Exposure of the tumours to higher than 40Gy significantly increased the tumour to blood ratios with both specific and non-specific antibody (P<0.001). Specific antibody had approximately a 6-fold in vivo binding advantage over the non-specific.
The vascular volume in the tumour and normal tissues was measured using 99Tcm 04 red blood cells. Vascular permeability was determined by measuring the amount of 1251-labelled non-specific antibody extravasated out of the tumour vasculature during 1 h. Vascular volume in the tumour was found to be significantly decreased after expo-sure to higher doses than 40Gy (P<0.001). Vascular permeability in tumours was higher in all radiation experiments when compared to non-irradiated values but the increases were not significant. We conclude that external irradiation increases specific and non-specific antibody uptake by tumour possibly due to increased permeability, even though vascular volume of the tumour is decreased. Carcinoma associated antigen (CA-50) is a tumour associated carbohydrate antigen, defined by the monoclonal antibody C50, which has been raised against a colorectal adenocarcinoma cell line. The aim of this study was to assess whether CA-50 can differentiate patients with gynaecological malignancies from normal subjects and those with benign disease. A radioimmunoassay was used for the detection of CA-50 in the serum of 50 normal subjects, 26 patients with benign disease and 48 patients with gynaecological malignancies. Serum levels in normal subjects and 21 out of 26 patients (81%) with benign disease were below 17Uml-1, while 27 out of 48 patients (56%) with carcinoma had levels above 17Uml-1. The sensitivities for cervical, endometrial and ovarian carcinomas were 48, 75 and 67% respectively. In patients with cervical carcinoma, the sensitivity was 46% for stage I carcinoma, 36% for stage II and 71% for stages III and IV. Therefore, this test may prove useful in the diagnosis of patients with gynaecological carcinomas. Carcinoma associated antigen (CA-50) is a tumour associated carbohydrate antigen, defined by the monoclonal antibody C50, which has been raised against a colorectal adenocarcinoma cell line. The aim of this study was to assess whether CA-50 can differentiate patients with carcinomas, from normal subjects and those with benign disease. A radioimmunoassay was used for the detection CA-50 in the serum of 50 normal subjects, 72 patients with benign disease and 239 patients with carcinoma of the gastrointestinal tract. Serum levels in normal subjects and 67 out of 72 patients (93%) with benign disease were below 17Uml-1, while 157 out of 239 patients (66%) with carcinoma had levels above 17Uml-. The sensitivities for the various carcinomas were as follows: pancreatic 92% (26 patients), gastric 75% (24), oesophageal 71% (21), liver 66% (91) and colorectal 51% (77). In patients with colorectal carcinoma, the sensitivity was 22% for Dukes' A carcinoma, 29% for Dukes' B, 59% for Dukes' C and 73% for metastatic disease. The CA-50 levels were elevated in 7 out of 9 patients (78%) who developed recurrence following curative surgery. In patients with liver carcinoma, the sensitivity was 70% for cholangiocarcinoma, 54% for hepatocellular carcinoma and 58% for metastatic liver disease. Therefore, this test may prove useful in the diagnosis and monitoring of patients with gastrointestinal carcinomas. Carcinoma associated antigen (CA-50) is a tumour associated carbohydrate antigen, defined by the monoclonal antibody C50, which has been raised against a colorectal adenocarcinoma cell line. The aim of this study was to assess whether CA-50 can differentiate patients with urological carcinomas from normal subjects and those with benign disease. A radioimmunoassay was used for the detection of CA-50 in the serum of 50 normal subjects, 86 patients with benign disease and 104 patients with urological carcinomas. Serum levels in all 50 normal subjects and 83 of 86 patients (97%) with benign disease were below 17 U ml -1, while 49 of 104 patients (47%) with carcinoma had levels above 17Uml-. The sensitivities for prostatic, bladder and renal carcinomas were 43%, 62% and 47% respectively. In patients with prostatic carcinoma, the sensitivities were 0% for well differentiated carcinomas, 33% for moderately differentiated carcinomas, 67% for poorly differentiated carcinomas and 71% for metastatic disease. The sensitivities for non-invasive and invasive bladder carcinomas were 42% and 89% respectively. Therefore this test may prove useful in the diagnosis of patients with urological malignancies.
Cross-linking of mouse monoclonal antibodies into tetramolecular antibody complexes using rat monoclonal antiisotype antibodies CEA, CA19-9 and CA50 are tumour associated antigens defined by monoclonal antibodies. The aim of this study was to determine whether combined use of CEA, CA19-9 and CA50 could improve diagnostic accuracy.
An immunoradiometric assay was used for the detection of CEA and CAl9-9 and the Delfia system for CA50. Serum was collected from 65 normal subjects, 40 with hepatobiliary carcinoma (26 primary, 14 secondary and 17 with benign hepatobiliary disease). The cut-off levels were calculated as the mean of the control group plus 2 standard deviations. The results are shown in the CEA, CA19-9 and CA50 are tumour associated antigens defined by monoclonal antibodies which have been raised against adenocarcinoma cell lines. No single antibody alone is specific for the detection of pancreatic malignancy and the aim of this study was to determine whether the combined use of CEA, CA19-9 and CA50 would improve diagnostic accuracy. An immunoradiometric assay was used for the detection of CEA and CA19-9 and the Delfia system for DA50. Serum In order to improve the specificity we used multivariant discriminant analysis on the combination of antibodies. This showed that 96% of the malignant group, 13% of the pancreatitis group and 11% of the normal group were positive with an overall correct classification of 91% into the three groups (multivariant discriminant analysis P <0.05). Combined use of CEA, CA19-9 and CA50 improves diagnostic accuracy and may be useful in differentiating benign from malignant disease. Monoclonal antibodies (MAbs) were produced in mice immunised by BT-20, a human breast adenocarcinoma cell line. The screening of these MAbs was performed by both ELISA and indirect immunofluorescence (IF) techniques using breast cancer cell lines and fresh frozen tissues. Hybridomas recognising BT-20 cells but negative with HBL-100 (putative normal epithelial cell line of breast origin) were retained for further studies. The biochemical characterisation of one of these MAbs, BCD-F2, has been determined and showed that it recognises a breast cancer associated antigen of Mr 48,000 which appears to be a N-acetyl-D-glycosamine carbohydrate side chain on a glycoprotein. In the present study using immunohistochemical techniques, shown to react with 98% (92% strongly and 6% weakly) of primary breast carcinomas. BCD-F2 also reacted with 82% (32% strongly and 50% weakly) of carcinomas from extramammary origin and did not recognise sarcomas, lymphomas or seminomas. These results suggest that BCD-F2 has potential clinical use in (a) the differential diagnosis between carcinomas from sarcomas and lymphomas, (b) the detection of micro-metastases in lymph nodes and (c) the identification of neoplastic cells in fine needle aspirates and biopsies. An 8-year-old girl presented with medullary carcinoma of thyroid metastatic to cervical nodes on right side of neck. Following total thyroidectomy and block dissection of right cervical lymph nodes (Nov. 1986) serum calcitonin remained elevated at 2,000-2,500 ng 1-1 (preop. 12,000 ng l-).
To detect evidence of occult disease, postoperative investigations included pentavalent DMSA (-ve) and MIBG (-ve IS was true positive in 8/9 (90%) patients whereas CT in 6/9 (67%) patients. Of the 3 patients not undergoing SL, IS was positive in all of them whereas clinical examination and abdominal CT scan were negative. All 3 patients had subsequent clinical relapse at 3, 4 and 5 months. The IS true positivity was 92% (11/12 patients) whereas CT was 50% (6/12%).
We conclude that IS with intraperitoneal administration of 13II-labelled MoAb can accurately detect the presence of residual disease in ovarian cancer. In this pilot study it proved more sensitive than abdominal CT scan. To overcome this problem we have biotinylated our primary antibodies (AUA1 and CEA) and injected each separately intra-peritoneally into nude mice bearing simultaneous subcutaneous and intraperitoneal xenografts of the human tumour 'LOVO' (a cell line established from an adenocarcinoma of the colon). Twenty-four hours after injection, the animals were sacrificed, tumours and control organs were studied. Antibody was demonstrated on frozen sections by incubating sections with avidin biotin peroxidase complex.
We compared the in vivo penetration and distribution of these antibodies on intraperitoneal and subcutaneous tumours as well as control organs. The antibody penetration was restricted to the thin layer of tumour cells adjacent to the vascular stroma in large solid subcutaneous and intraperitoneal tumours, whereas in very small intraperitoneal tumours, antibody penetration was complete. These findings were similar to our autoradiographic results.
This study demonstrates that employing biotinylated antibodies for in vivo localisation studies provides superior resolution of antibody binding for morphological assessment compared to autoradiography. Localisation of a biotin label is more precise and will permit ultrastructural studies. A simple rapid method, not requiring blood cell separation, is required for platelet labelling in the diagnosis of DVT. We have previously reported our preliminary clinical findings with an i.lv. monoclonal antibody (P256), raised in mice labelled with "'In and specific for primate platelet glycoprotein Ilb/Illa complex. The effect of P256 and its Fab; fragments on in vitro platelet function have been assessed by measuring platelet aggregation in whole blood, platelet rich plasma and gel filtered platelets. The F(ab')2 fragment caused consistently less aggregation than the whole antibody, whilst the monovalent Fab' fragment had no effect. The monovalent Fab' fragment was therefore investigated for its ability to image thrombus in vivo. After labelling with "'In, via the bifunctional chelate DTPA, the P256 Fab retained reactivity and specificity for primate platelets. Thrombus was induced in M.fascicularis by i.v. injection of iron microspheres and localised with an externally applied magnetic field. Thrombus was confirmed by venography and imaged with "'In-P256 Fab'. The venogram and scintigram were both positive at 1 and 48 h after thrombus induction. These initial studies show good correlation between imaging with P256 Fab' fragment and venography for detection of DVT. showed equally strong reactions with both cell types. A clear-cut preference of the reactions with basal cells was seen with the antibodies HMFG-1 and 115F5. The subclassification of the antibodies does fit epitope mapping, by conventional blocking studies, reported in the literature.
